logo

Antidepressants (Adult dosing)

amitriptyline (Elavil ®): bupropion ( Wellbutrin®/ Zyban®)
citalopram (Celexa ®): desipramine (Norpramin ®):
doxepin (Sinequan ®): duloxetine (Cymbalta ® )
escitalopram (Lexapro ® ) : fluoxetine (Prozac® ) :
fluvoxamine (Luvox ®): imipramine (Tofranil ®):
mirtazapine (Remeron ®): nefazodone (Serzone ®):
nortriptyline (Pamelor ®): paroxetine (Paxil ®):
sertraline (Zoloft ®): trazodone (Desyrel ®):
venlafaxine (Effexor ®) vilazodone HCL -VIIBRYD™
vortioxetine - BRINTELLIX® DISCONTINUATION SYNDROME
antidepressants table
Approximate equivalent dosages of antidepressants:
Citalopram 20 mg
Escitalopram 5-10 mg
Fluvoxamine 100 mg
Fluoxetine 20 mg
Paroxetine 20 mg
Sertraline 50-75 mg
Venlafaxine 75 mg

amitriptyline (Elavil ®): top of page

Class:  Tricyclic - Tertiary Amine
Dosing (Adults):
Depression
: Initially, 25-100 mg orally at bedtime or give in divided doses. Gradually increase to usual effective dose of 50 to 300mg/day.

Chronic pain (adjunct): Initially, 25 mg at bedtime - may increase as tolerated to 100 mg/day.

Migraine prophylaxis: Oral: Initial: 10-25 mg at bedtime; usual dose: 150 mg; reported dosing ranges: 10-400 mg/day.

Elderly: Depression: Oral: Initial: 10-25 mg at bedtime; dose should be increased in 10-25 mg increments every week if tolerated; dose range: 25-150 mg/day

Dosing interval in hepatic impairment: Use with caution and monitor plasma levels and patient response

Supplied:  Tablet: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg

bupropion  ( Wellbutrin ® /  Zyban ®  ) top of page

Class:  Aminoketone
Dosing (Adults):
Depression
:
Immediate release: 100 mg 3 times/day; begin at 100 mg twice daily; may increase to a maximum dose of 450 mg/day

Sustained release: Initial: 150 mg/day in the morning; may increase to 150 mg twice daily by day 4 if tolerated; target dose: 300 mg/day given as 150 mg twice daily; maximum dose: 400 mg/day given as 200 mg twice daily

Extended release: Initial: 150 mg/day in the morning; may increase as early as day 4 of dosing to 300 mg/day; maximum dose: 450 mg/day

Smoking cessation (Zyban®): Initiate with 150 mg once daily for 3 days; increase to 150 mg twice daily; treatment should continue for 7-12 weeks

Elderly: Depression: 50-100 mg/day, increase by 50-100 mg every 3-4 days as tolerated; there is evidence that the elderly respond at 150 mg/day in divided doses, but some may require a higher dose

Dosing adjustment/comments in renal impairment: Effect of renal disease on bupropion's pharmacokinetics has not been studied; elimination of the major metabolites of bupropion may be affected by reduced renal function. Patients with renal failure should receive a reduced dosage initially and be closely monitored.

Dosing adjustment in hepatic impairment:
Mild to moderate hepatic impairment: Use with caution and/or reduced dose/frequency.
Severe hepatic cirrhosis: Use with extreme caution; maximum dose:
Wellbutrin®: 75 mg/day
Wellbutrin SR®: 100 mg/day or 150 mg every other day
Wellbutrin XL™: 150 mg every other day
Zyban®: 150 mg every other day

Supplied:
Tablet, as hydrochloride (Wellbutrin®): 75 mg, 100 mg

Tablet, extended release, as hydrochloride (Wellbutrin XL™): 150 mg, 300 mg

Tablet, sustained release, as hydrochloride: 100 mg, 150 mg [equivalent to Wellbutrin® SR], 150 mg [equivalent to Zyban®]

Wellbutrin® SR: 100 mg, 150 mg, 200 mg

Zyban®: 150 mg

citalopram (Celexa ®):  top of page

Class:  Selective serotonin reuptake inhibitor (SSRI)
Adults: Depression:

FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide) - Safety Announcement:
[8-24-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Studies did not show a benefit in the treatment of depression at doses higher than 40 mg per day.
 
Increase in the Corrected QT Interval for Citalopram (FDA Analysis)
Citalopram Dose Increase in QT Interval (ms) 90% Confidence Interval (ms)
20 mg/day 8.5 (6.2, 10.8)
60 mg/day 18.5 (16.0, 21.0)
40 mg/day 12.6* (10.9, 14.3)*

Initial: 20 mg/day, generally with an increase to 40 mg/day; doses of more than 40 mg are not usually necessary and should be avoided.

Supplied
Solution, oral: 10 mg/5 mL (240 mL) [alcohol free, sugar free; peppermint flavor]
Tablet: 10 mg, 20 mg, 40 mg

desipramine (Norpramin ®):  top of page

Class:  Tricyclic - Secondary Amine
Dosing
Adolescents: Depression: Initial: 25-50 mg/day; gradually increase to 100 mg/day in single or divided doses (maximum: 150 mg/day)

Adults:
Depression: Initial: 75 mg/day in divided doses; increase gradually to 150-200 mg/day in divided or single dose (maximum: 300 mg/day)

Cocaine withdrawal (unlabeled use): 50-200 mg/day in divided or single dose

Elderly: Depression: Initial dose: 10-25 mg/day; increase by 10-25 mg every 3 days for inpatients and every week for outpatients if tolerated; usual maintenance dose: 75-100 mg/day, but doses up to 150 mg/day may be necessary


Monitor blood pressure and pulse rate prior to and during initial therapy evaluate mental status; monitor weight; ECG in older adults and those patients with cardiac disease; blood levels are useful for therapeutic monitoring.

Supplied
Tablet, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg

doxepin (Sinequan ®): top of page

Class:  Tricyclic - Tertiary Amine
Dosing:
Oral (entire daily dose may be given at bedtime):
Depression or anxiety:
Adolescents: Initial: 25-50 mg/day in single or divided doses; gradually increase to 100 mg/day

Adults: Initial: 25-150 mg/day at bedtime or in 2-3 divided doses; may gradually increase up to 300 mg/day; single dose should not exceed 150 mg; select patients may respond to 25-50 mg/day

Elderly: Use a lower dose and adjust gradually

Chronic urticaria, angioedema, nocturnal pruritus: Adults and Elderly: 10-30 mg/day

Dosing adjustment in hepatic impairment:
Use a lower dose and adjust gradually

Supplied
Capsule, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg
Solution, oral concentrate, as hydrochloride (Sinequan®): 10 mg/mL (120 mL)

duloxetine (Cymbalta ® ) top of page

Class:  Norephinephrine / serotonin reuptake inhibitor
Dosing (Adults):
Depression: Treatment of major depressive disorder: Initial: 40-60 mg/day; dose may be divided (ie, 20 or 30 mg twice daily) or given as a single daily dose of 60 mg; maximum dose: 60 mg/day

Diabetic neuropathy:: 60 mg orally once daily. Lower initial doses may be considered in patients where tolerability is a concern and/or renal impairment is present.
Management of chronic pain syndromes (unlabeled use): 60 mg once daily

Management of stress incontinence (unlabeled use): 40 mg twice daily

Elderly: Treatment of major depressive disorder: Initial dose: 20 mg 1-2 times/day; increase to 40-60 mg/day as a single daily dose or in divided doses

Renal dosing:
[CRCL 30-50 ml/min]: Lower initial doses may be considered with titration guided by response and tolerability.
[< 30 ml/min]: Not recommended.

Supplied:: 20 mg, 30 mg, 60 mg capsule.

escitalopram (Lexapro ® ) : top of page

Class:  Selective serotonin reuptake inhibitor (SSRI)
Mechanism of Action
The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).


Dosing: Oral:
Adults
: Depression, GAD: Initial: 10 mg/day; dose may be increased to 20 mg/day after at least 1 week

Elderly: 10 mg/day; bioavailability and half-life are increased by 50% in the elderly

Dosage adjustment in renal impairment:
Mild to moderate impairment: No dosage adjustment needed.
Severe impairment: Clcr<20 mL/minute: Use caution.

Dosage adjustment in hepatic impairment: 10 mg/day

Supplied:
Solution, oral: 1 mg/mL (240 mL)
Tablet: 5 mg, 10 mg, 20 mg

fluoxetine (Prozac® ) :  top of page

Class:  Selective serotonin reuptake inhibitor (SSRI)
Dosing (Adults): Depression, OCD, PMDD, bulimia: Initially, 20mg orally every morning - may increase after several weeks by 20 mg/day increments. Usual effective dose: 20-40mg/day. Maximum: 80mg/day.

Obsessive compulsive disorder (OCD): 40-80 mg/day.
PMDD: 20 mg/day continuously, or 20 mg/day starting 14 days prior to menstruation and through first full day of menses (repeat with each cycle).

Panic disorder: Initially, 10 mg/day. After 1 week, increase to 20 mg/day. May increase after several weeks. Doses >60 mg/day have not been evaluated.

[Supplied: 10, 20 mg, 40mg capsule. Long-acting delayed release capsule: 90 mg]

fluvoxamine (Luvox ®):  top of page

ClClass:  Selective serotonin reuptake inhibitor (SSRI)
Dosing (Adults):
OCD
: Initially, 50 mg orally at bedtime, usual effective: 100-300 mg/day divided into 2 doses. Maximum: 300mg/day.

Elderly: Reduce dose, titrate slowly

Dosage adjustment in hepatic impairment: Reduce dose, titrate slowly

Supplied
Tablet: 25 mg, 50 mg, 100 mg

imipramine (Tofranil ®): top of page

Class:  cyclic - Tertiary Amine
 (Adults): Initially, 25 mg orally at bedtime, increase gradually to usual effective dose 50-300 mg/day.

Dosing Oral: 
Children:

Enuresis: >/= 6 years: Initial: 25 mg at bedtime, if inadequate response still seen after 1 week of therapy, increase by 25 mg/day; dose should not exceed 2.5 mg/kg/day or 50 mg at bedtime if 6-12 years of age or 75 mg at bedtime if >/= 12 years of age

Adolescents: Depression: Initial: 30-40 mg/day; increase gradually; maximum: 100 mg/day in single or divided doses

Adults: Depression: Initial: 25 mg 3-4 times/day, increase dose gradually, total dose may be given at bedtime; maximum: 300 mg/day

Elderly: Initial: 10-25 mg at bedtime; increase by 10-25 mg every 3 days for inpatients and weekly for outpatients if tolerated; average daily dose to achieve a therapeutic concentration: 100 mg/day; range: 50-150 mg/day

Supplied
Capsule, as pamoate (Tofranil-PM®): 75 mg, 100 mg, 125 mg, 150 mg

Tablet, as hydrochloride (Tofranil®): 10 mg, 25 mg, 50 mg [generic tablets may contain sodium benzoate]

mirtazapine (Remeron ®): top of page

Class:  Tetracyclic
Dosing (Adults):
Depression
: Initially, 15 mg orally at bedtime. Usual effective dose: 15-45 mg/day. (Dose increases made no more frequently than every 1-2 weeks. )

Use: May be particularly helpful in depressed patients with insomnia due to its sedative properties.

Mechanism of Action:
Evidence gathered in preclinical studies suggests that mirtazapine enhances central noradrenergic and serotonergic activity. These studies have shown that mirtazapine acts as an antagonist at central presynaptic alpha2 adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity.

Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors. Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors.

Mirtazapine is a potent antagonist of histamine (H1) receptors, a property that may explain its prominent sedative effects.

Mirtazapine is a moderate peripheral alpha1 adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use.

Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use.


Dosage adjustment in renal impairment:
Clcr 11-39 mL/minute: 30% decreased clearance
Clcr<10 mL/minute: 50% decreased clearance

Dosage adjustment in hepatic impairment: Clearance decreased by 30%

Supplied: 1: 15 mg, 30 mg, 45 mg tablet. Orally-disintegrating tablet: 15 mg, 30 mg, 45 mg.

nefazodone (Serzone ®):  top of page

Class:  Phenylpiperazine
Dosing (Adults):
Depression
: Initially, 100mg orally twice daily. Usual effective dose: 150-300mg orally twice daily. Maximum: 600 mg/day.
[Supplied: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tablet.]

nortriptyline (Pamelor ®): top of page

Class:  Tricyclic - Secondary Amine
Dosing (Ad (Adults):
------------------------------------------------------------
Depression:
Adults: Initially, 25mg orally 1 to 4 times daily.
Usual effective dose: 50-150 mg/day..

Elderly ( Note: Nortriptyline is one of the best tolerated TCAs in the elderly)
Initial: 10-25 mg at bedtime.    Dosage can be increased by 25 mg every 3 days for inpatients and weekly for outpatients if tolerated.   Usual maintenance dose: 75 mg as a single bedtime dose or 2 divided doses; however, lower or higher doses may be required to stay within the therapeutic window

Chronic urticaria, angioedema, nocturnal pruritus (unlabeled use): Adults: Oral: 75 mg/day

Smoking cessation (unlabeled use): Adults: 25-75 mg/day beginning 10-14 days before "quit" day; continue therapy for >/= 12 weeks after "quit" day

Dosing adjustment in hepatic impairment: Lower doses and slower titration dependent on individualization of dosage is recommended

Supplied
Capsule, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg

paroxetine (Paxil ®):  top of page

Class:  Selective serotonin reuptake inhibitor (SSRI)
Dosing (Adults):
Depression: Initially, 20 mg orally every morning. Usual effective dose: 20-50 mg/day. Maximum: 50mg/day. (Controlled release tablet - Paxil CR): Initially, 25 mg once daily. Increase if needed by 12.5 mg/day increments at intervals of at least 1 week. Maximum dose: 62.5 mg/day.
OCD / Panic attacks: Initially, 10-20mg/day. Increase if needed by 10 mg/day increments at intervals of at least 1 week. Usual effective dose: 10-60 mg/day. Recommended dose: 40 mg/day. Maximum: 60 mg/day. (Controlled release tablet - Paxil CR): Panic attacks: Initially,12.5 mg once daily. Increase if needed by 12.5 mg/day at intervals of at least 1 week. maximum dose: 75 mg/day.

GAD: Initially, 20 mg once daily every morning. If dose is increased, adjust in increments of 10 mg/day at 1 week intervals.

PMDD: (Controlled release tablet - Paxil CR): Initially, 12.5 mg once daily in the morning. May be increased to 25 mg/day. Dosing changes should occur at intervals of at least 1 week. May be given daily throughout the menstrual cycle or limited to the luteal phase.

PTSD: Initially, 20 mg orally every morning. Usual effective dose: 20-50 mg/day. Maximum: 50mg/day.

Supplied: 10 mg, 20 mg, 30 mg, 40 mg tablet. Controlled release tablet: 12.5 mg, 25 mg, 37.5 mg.

sertraline (Zoloft ®):  top of page

Class:  Selective serotonin reuptake inhibitor (SSRI)
Dosing (Adults):
Depression / OCD: Initially, 50 mg orally once daily. Usual effective dose: 50-200 mg/day. May increase daily dose, at intervals of not less than 1 week. Maximum: 200 mg/day.
Panic attacks: Initially, 25mg orally once daily. Maximum: 200 mg/day.
PMDD: Usual dose: 50 mg orally once daily throughout menstrual cycle or limited to the luteal phase of menstrual cycle. , depending on physician assessment. May titrate up to 100 - 150mg if poor response.

Supplied: 25 mg, 50 mg, 100 mg tablet. Oral concentrate: 20 mg/ml (60 ml.)

trazodone (Desyrel ®): top of page

ClasClass:  Triazolopyridine
Oral: Therapeutic effects may take up to 6 weeks to occur; therapy is normally maintained for 6-12 months after optimum response is reached to prevent recurrence of depression.

Dosing (Adults):
Depression: Initial: 150 mg/day in 3 divided doses (may increase by 50 mg/day every 3-7 days); maximum: 600 mg/day.   Dosing after meals may decrease lightheadedness and postural hypotension.

Sedation/hypnotic (unlabeled use): 25-50 mg at bedtime (often in combination with daytime SSRIs); may increase up to 200 mg at bedtime.  Dosing after meals may decrease lightheadedness and postural hypotension.

Elderly: 25-50 mg at bedtime with 25-50 mg/day dose increase every 3 days for inpatients and weekly for outpatients, if tolerated; usual dose: 75-150 mg/day

Supplied: 50 mg, 100 mg, 150 mg, 300 mg tablet.

venlafaxine (Effexor ®)  top of page

Class:  Norephinephrine / serotonin reuptake inhibitor
Phenethylamine (Non-tricyclic).  (Potent inhibitor of serotonin and norepinephrine reuptake + weak inhibitor of dopamine reuptake. )

Dosing: Adults:
Depression:
Immediate-release tablets: 75 mg/day, administered in 2 or 3 divided doses, taken with food; dose may be increased in 75 mg/day increments at intervals of at least 4 days, up to 225-375 mg/day

Extended-release capsules: 75 mg once daily taken with food; for some new patients, it may be desirable to start at 37.5 mg/day for 4-7 days before increasing to 75 mg once daily; dose may be increased by up to 75 mg/day increments every 4 days as tolerated, up to a maximum of 225 mg/day

GAD, social anxiety disorder: Extended-release capsules: 75 mg once daily taken with food; for some new patients, it may be desirable to start at 37.5 mg/day for 4-7 days before increasing to 75 mg once daily; dose may be increased by up to 75 mg/day increments every 4 days as tolerated, up to a maximum of 225 mg/day

Note: When discontinuing this medication after more than 1 week of treatment, it is generally recommended that the dose be tapered. If venlafaxine is used for 6 weeks or longer, the dose should be tapered over 2 weeks when discontinuing its use.

Dosing adjustment in renal impairment: Clcr 10-70 mL/minute: Decrease dose by 25%; decrease total daily dose by 50% if dialysis patients; dialysis patients should receive dosing after completion of dialysis

Dosing adjustment in moderate hepatic impairment: Reduce total daily dosage by 50%

Administration
Administer with food.
Extended release capsule: Swallow capsule whole; do not crush or chew. Alternatively, contents may be sprinkled on a spoonful of applesauce and swallowed immediately without chewing; followed with a glass of water to ensure complete swallowing of the pellets.

Supplied: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg tablet. 37.5 mg, 75 mg, 150 mg extended release capsule.

vilazodone HCL -VIIBRYD™ top of page

INDICATIONS AND USAGE
VIIBRYD is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, randomized, double-blind, placebo-controlled trials in adult patients with a diagnosis of MDD.

Major depressive disorder consists of one or more major depressive episodes. A major depressive episode (DSM-IV-TR) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.

DRUG INTERACTIONS
MAOIs: Do not use VIIBRYD concomitantly with an MAOI or within 14 days of stopping or starting an MAOI.

CYP3A4 inhibitors: The VIIBRYD dose should be reduced to 20 mg when co-administered with CYP3A4 strong inhibitors.

CYP3A4 inducers: Concomitant use of VIIBRYD with inducers of CYP3A4 can result in inadequate drug concentrations and may diminish effectiveness. The effect of CYP3A4 inducers on systemic exposure of vilazodone has not been evaluated.


USE IN SPECIFIC POPULATIONS
Pregnancy: There are no controlled human data regarding VIIBRYD use during pregnancy. Use only if the potential benefits outweigh the potential risks.

Nursing Mothers: There are no human data regarding VIIBRYD concentrations in breast milk. Women should breast feed only if the potential benefits outweigh the potential risks.

Pediatric Use: The safety and efficacy of VIIBRYD in pediatric patients have not been studied.

Geriatric Use: No dose adjustment is recommended on the basis of age.

Hepatic Impairment: No dose adjustment is recommended in patients with mild or moderate hepatic impairment. VIIBRYD has not been studied in patients with severe hepatic impairment.

DOSAGE AND ADMINISTRATION
SUMMARY:
The recommended dose for VIIBRYD is 40 mg once daily.
VIIBRYD should be titrated to the 40 mg dose, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then increased to 40 mg once daily.
VIIBRYD should be taken with food. Administration without food can result in inadequate drug concentrations and may diminish effectiveness.
When discontinuing treatment, reduce the dose gradually.
---------------

DOSAGE AND ADMINISTRATION

Initial Treatment of Major Depressive Disorder
The recommended dose for VIIBRYD is 40 mg once daily. VIIBRYD should be titrated, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then an increase to 40 mg once daily. VIIBRYD should be taken with food. VIIBRYD blood concentrations (AUC) in the fasted state can be decreased by approximately 50% compared to the fed state, and may result in diminished effectiveness in some patients.


Maintenance/Continuation/Extended Treatment
The efficacy of VIIBRYD has not been systematically studied beyond 8 weeks. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be reassessed periodically to determine the need for maintenance treatment and the appropriate dose for treatment.


Dosing in Special Populations
Pregnant Women: Neonates exposed to serotonergic antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. When treating pregnant women with VIIBRYD, consider whether the potential benefits outweigh the potential risks of treatment.

Nursing Mothers: There are no clinical data regarding the effect of VIIBRYD on lactation and nursing. Breastfeeding in women treated with VIIBRYD should be considered only if the potential benefit outweighs the potential risk.

Pediatric Patients: The safety and efficacy of VIIBRYD have not been studied in pediatric patients.

Geriatric Patients: No dose adjustment is recommended on the basis of age.

Hepatic Impairment: No dose adjustment is recommended in patients with mild or moderate hepatic impairment. VIIBRYD has not been studied in severe hepatic impairment.

Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment.

Gender: No dose adjustment is recommended on the basis of gender.


Discontinuing Treatment
Discontinuation symptoms have been reported with discontinuation of serotonergic drugs such as VIIBRYD. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients for these symptoms when discontinuing VIIBRYD. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate.


Monoamine Oxidase Inhibitors (MAOI)
At least 14 days must elapse between discontinuation of an MAOI and initiation of therapy with VIIBRYD. In addition, at least 14 days must be allowed after stopping VIIBRYD before starting an MAOI.

HOW SUPPLIED
DOSAGE FORMS AND STRENGTHS
VIIBRYD Tablets are available as 10 mg, 20 mg and 40 mg immediate-release, film-coated tablets.

10 mg pink, oval tablet, debossed with 10 on one side

20 mg orange, oval tablet, debossed with 20 on one side

40 mg blue, oval tablet, debossed with 40 on one side
top of page

Disclaimer

Listed dosages are for - Adult patients ONLY. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. GlobalRPH does not directly or indirectly practice medicine or provide medical services and therefore assumes no liability whatsoever of any kind for the information and data accessed through the Service or for any diagnosis or treatment made in reliance thereon.

David F. McAuley, Pharm.D., R.Ph.  GlobalRPh Inc.
more Career Center image description
Medical Calculators - A thru Z
Lab Values - A thru Z